Assessment of the risk of haemorrhage and its control following minor oral surgical procedures in patients on anti-platelet therapy: a prospective study

被引:30
|
作者
Girotra, C. [1 ]
Padhye, M. [1 ]
Mandlik, G. [1 ]
Dabir, A. [1 ]
Gite, M. [1 ]
Dhonnar, R. [1 ]
Pandhi, V. [1 ]
Vandekar, M. [1 ]
机构
[1] Dr DY Patil Dent Coll & Hosp, Nerul, Navi Mumbai, India
关键词
anti-platelet therapy; minor oral surgery; risk of prolonged postoperative bleeding; local hemostatic measures; DOSE ASPIRIN THERAPY; MYOCARDIAL-INFARCTION; CORONARY SYNDROMES; SINGLE; PREVENTION; WITHDRAWAL; SURGERY; SOCIETY; DEATH;
D O I
10.1016/j.ijom.2013.08.014
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Controversy exists concerning the suspension or maintenance of antiplatelet drugs before elective surgical procedures. We assessed the association of the risk of prolonged postoperative bleeding with anti-platelet therapy by type of minor surgical procedure and the association between anti-platelet therapy and the level of hemostatic measures required. Five hundred and forty-six patients were included in the study group: those on aspirin (n = 310), clopidogrel (n = 97), and aspirin + clopidogrel dual therapy (n = 139); the control group comprised 575 healthy individuals. Cramer's V test was significant (P < 0.05) but showed a weak association between anti-platelet therapy and prolonged immediate postoperative bleeding. Compared to controls, the odds ratio revealed that the risk of prolonged bleeding in the immediate postoperative period was significantly higher with dual therapy, followed by clopidogrel and aspirin. Prolonged bleeding occurred in 22 patients in the study group and 20 in the control group, and was successfully controlled with local hemostatic measures. Fisher's exact test showed a significant association between dual therapy and higher levels of hemostatic measures (P = 0.004; P = 0.035). Prolonged bleeding in patients on anti-platelet therapy was independent of the type of minor surgical procedure. The greatest risk of prolonged bleeding was found in patients on dual therapy; this required higher levels of hemostatic measures.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 50 条
  • [21] Risk and Benefit of Proton Pump Inhibitor for Patients Undergoing Anti-Platelet Therapy Including Clopidogrel
    Furuta, Takahisa
    INTERNAL MEDICINE, 2009, 48 (21) : 1847 - 1848
  • [22] Prospective study on the clinical significance of specific anti-platelet autoantibodies in patients with primary immune thrombocytopenia
    Fabris, F
    Cordiano, I
    Sartori, R
    Tassan, R
    Ramon, R
    Girolami, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 364 - 365
  • [23] Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy
    Shin, Dong Geum
    Kim, Sunhwa
    Kim, Yoo Ri
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (01)
  • [24] Addition of dual anti-platelet therapy to oral anticoagulation, in patients with atrial fibrillation, does not increase risk of major hemorrhage: analysis from the ACTIVE W study
    Karthikeyan, G.
    Yuan, F.
    Pogue, J.
    Hohnloser, S. H.
    Pfeffer, M. A.
    Connolly, S. J.
    EUROPEAN HEART JOURNAL, 2008, 29 : 745 - 746
  • [25] A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet
    Elad, Sharon
    Chackartchi, Tali
    Shapira, Lior
    Findler, Mordechai
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2008, 35 (04) : 342 - 345
  • [26] A survey of joint aspiration, injection, and other procedures by different clinicians: Guidelines development for patients on anti-coagulants and anti-platelet therapy
    Koualty, W
    Pal, B
    Muddu, B
    Snow, S
    RHEUMATOLOGY, 2005, 44 : I57 - I58
  • [27] Anti-platelet therapy in ST-elevation myocardial infarction patients: balancing ischaemic and bleeding risk
    Martinez, Carolina Sanchez
    Akin, Muharrem
    Tillmanns, Jochen
    Bauersachs, Johann
    Schaefer, Andreas
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (05) : e19 - e22
  • [28] INCIDENCE OF HEMATURIA FOLLOWING TUR-BT AMONG 1315 PATIENTS RECEIVING ANTI-PLATELET THERAPY.
    Egerdie, Blair
    Chawla, Shanta
    Nardo, Chris
    Denes, Bela
    JOURNAL OF UROLOGY, 2010, 183 (04): : E564 - E565
  • [29] IS IT SAFE TO CONTINUE ANTI-PLATELET AND ANTICOAGULATION THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS NEPHROLITHOTOMY (PCNL)? A NESTED CASE CONTROL STUDY.
    Vollstedt, Annah
    Bustos, Natalia Hernandez
    Eisner, Brian
    Dagrosa, Lawrence
    Pais, Vernon
    JOURNAL OF UROLOGY, 2016, 195 (04): : E506 - E506
  • [30] Unanticipated Platelet Function Fluctuations Occur During The First 8 Hours After Neurointerventional Procedures In Patients Receiving Dual Anti-platelet Therapy
    Allen, Travis S.
    Austin, Matthew
    Santillan, Alejandro
    Loy, David
    STROKE, 2022, 53